Organisation
Intellectual Property
Administrative Office
Projects
1 - 10 of 13
- Targeting transcription factor addiction in acute leukemia (TaTFAL)From1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesotheliomaFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- MATATUM: Validation and druggability development of macrophage-specific targets in the tumor microenvironment.From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Targeting ZEB pathways to tackle aggressive (colorectal) cancer (ZENTACC).From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Towards a combined post-exposure prophylaxis and successful treatment of rabies in humansFrom1 Oct 2017 → 30 Sep 2020Funding: FWO research project
- Valorization of novel strategies for the prevention of viral infection and inhibition of viral replication.From1 Nov 2015 → TodayFunding: IOF - Industrial Research Fund, IOF - mandates
- iKap: Targeting nucleocytoplasmic transport for novel anti-cancer therapy.From1 Oct 2015 → 30 Nov 2019Funding: SBO (Strategic basic research)
- Targeting the chromatin for innovative cancer therapy.From1 Nov 2014 → 31 Oct 2018Funding: SBO (Strategic basic research)
- Nuclear-cytoplasmic transport as novel therapeutic target.From1 Oct 2014 → 30 Sep 2018Funding: IOF - Industrial Research Fund
- Development of novel selective ghrelin O-acyltransferase inhibitors for the treatment of obesity and obesity-related type 2 diabetesFrom1 Apr 2014 → 31 Mar 2015Funding: IOF - Industrial Research Fund
Publications
1 - 10 of 40
- Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model.(2022)
Authors: Tom Van Loy, Steven De Jonghe, Wouter Dheedene, Patrick Chaltin, Aernout Luttun, Dominique Schols
Pages: 293 - Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice(2021)
Authors: Patrick Chaltin
Number of pages: 24 - Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery(2020)
Authors: Rana Abdelnabi, Kim Donckers, Pieter Leyssen, Patrick Chaltin, Johan Neyts, Leen Delang
Number of pages: 11 - Functional expression and pharmacological modulation of TRPM3 in human sensory neurons(2020)
Authors: Laura Vangeel, Katrien De Clercq, Patrick Chaltin, Catherine Verfaillie, Joris Vriens, Thomas Voets
Pages: 2683 - 2695Number of pages: 13 - Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors(2018)
Authors: Suzanne Kaptein, Kai Henrik Dallmeier, Patrick Chaltin, Johan Neyts
Pages: 8390 - 8401Number of pages: 12 - Modifying Rap1-signalling by targeting Pde6 delta is neuroprotective in models of Alzheimer's disease(2018)
Authors: Wim Dehaen, Joris Winderickx, Patrick Chaltin
Number of pages: 21 - Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium(2018)
Authors: Carmen Mirabelli, Mieke Boon, Mark Jorissen, Patrick Chaltin, Johan Neyts, Dirk Jochmans
Pages: 1823 - 1829Number of pages: 7 - Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects(2018)
Authors: Nihed Draoui, Patrick Chaltin
Number of pages: 11 - Inhibitors of the Integrase–Transportin-SR2 interaction block HIV nuclear import(2018)
Authors: Jonas Demeulemeester, Jolien Blokken, Stéphanie De Houwer, Lieve Dirix, Arnaud Marchand, Patrick Chaltin, Frauke Christ, Zeger Debyser
Number of pages: 13 - 1-((2,4-Dichlorophenethyl)Amino)3-Phenoxypropan-2-ol Kills Pseudomonas aeruginosa through Extensive Membrane Damage(2018)
Authors: Valerie Defraine, Veerle Liebens, Toon Swings, Bram Weytjens, Kathleen Marchal, Arnaud Marchand, Patrick Chaltin, Maarten Fauvart, Jan Michiels
Number of pages: 13